CVS Health opens 10 drive-thru COVID-19 test sites in Kansas

CVS Health (NYSE:CVS) to open 10 new COVID-19 test sites at select CVS Pharmacy drive-thru locations across Kansas, on Friday, June 12.

These new sites will utilize self-swab tests and deliver on the company’s promise to establish 1,000 locations across the country and help enable a goal of processing up to 1.5M tests per month, contingent on availability of supplies and lab capacity.

https://seekingalpha.com/news/3582233-cvs-health-opens-10-drive-thru-covidminus-19-test-sites-in-kansas

FDA OKs Pfizer’s Neulasta biosimilar

The FDA approves Pfizer’s (NYSE:PFE) Nyvepria (pegfilgrastim-apgf), a bisimilar to Amgen’s (NASDAQ:AMGN) Neulasta, its sixth biosimilar approved in the U.S.
https://seekingalpha.com/news/3582254-fda-oks-pfizers-neulasta-biosimilar

ThermoGenesis files patent applications for detection of COVID-19 antibodies

ThermoGenesis Holdings (NASDAQ:THMO) has filed patent applications for a point-of-care device which improves the speed and accuracy of lateral flow immunoassays (LFIA) to detect COVID-19 IgM and IgG antibodies from a single drop of blood.

The applications have been filed in the U.S. in accordance with the USPTO COVID-19 prioritized examination Pilot Program.

COVID-19 LFIA reader will enable the user to simply slide the test cartridge into a portable reader, providing an instant readout which can be recorded into a database, and/or a cloud-based web portal.

https://seekingalpha.com/news/3582264-thermogenesis-files-patent-applications-for-detection-of-covidminus-19-antibodies

Lannett advances insulin glargine biosimilar

Based on FDA feedback, Lannett Company (NYSE:LCI) expects to file its U.S. marketing application for biosimilar insulin glargine (Sanofi’s Lantus) in calendar year 2022.
https://seekingalpha.com/news/3582256-lannett-advances-insulin-glargine-biosimilar

Anthem debuts decision support tools to aid in COVID-19 reopenings

Aimed at helping public health officials and business leaders’ plan to the reopening U.S. workplaces shuttered during the pandemic, Anthem (NYSE:ANTM) will make its C19 Explorer and C19 Navigator decision support tools available through its new portal.

C19 Explorer is an interactive dashboard on COVID-19 infection rates and community risk scores, including analysis and visualization that authorities and business leaders can use to assess a community’s readiness to reopen.

C19 Navigator is designed for Anthem employer customers to provide clinical insight and predictions to support the identification and clarification of next steps in the reopening process.

Anthem has released other tools over the past weeks to help stakeholders during the pandemic.

https://seekingalpha.com/news/3582261-anthem-debuts-decision-support-tools-to-aid-in-covidminus-19-reopenings

DarioHealth up big on remote patient monitoring deals

Thinly traded nano cap DarioHealth (NASDAQ:DRIO) has inked the first of two remote patient monitoring (RPM) contracts involving its turnkey RPM solution that integrates its open platform, application technology and the DarioEngage coaching platform.

The company does not disclose the size of the deal, but investors appear impressed. Shares are up 80% premarket on increased volume.

https://seekingalpha.com/news/3582277-dariohealth-up-big-on-remote-patient-monitoring-deals

Tenet Healthcare to update on business June 16

Tenet Healthcare (THC -5.7%) will host a conference call and webcast on Tuesday, June 16, at 10:00 am ET to update investors on its operations.

Current Q2 consensus is a loss/share of ($0.98) on revenues of $3.75B.

Current 2020 consensus is EPS of $1.18 on revenues of $17.34B.

https://seekingalpha.com/news/3582312-tenet-healthcare-to-update-on-business-june-16